The Bottom Line:

• Aurigene Oncology, a subsidiary of Dr. Reddy’s Laboratories (NSE: DRREDDY, NYSE: RDY), recently reported promising Phase 1 data for its novel CAR-T therapy, Ribrecabtagene autoleucel (DRL-1801), targeting relapsed/refractory multiple myeloma.
• All eight patients in the trial showed a 100% clinical response, with 62.5% achieving stringent complete remission.
•  Notably, there were no severe adverse effects such as high-grade Cytokine Release Syndrome (CRS) or neurotoxicity.
• Following these results, India’s drug regulator, DCGI, has approved the progression to Phase 2 trials.

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy’s Laboratories (NYSE: RDY) (BSE: DRREDDY), has reported positive Phase 1 results for Ribrecabtagene autoleucel (DRL-1801), India’s first autologous CAR-T cell therapy targeting multiple myeloma. This breakthrough represents a significant leap in cancer treatment in India, as it offers new hope for patients with relapsed or refractory multiple myeloma—a form of cancer known to be difficult to treat after multiple rounds of therapy.

The Phase 1 trial, known as the SWASTH study, included eight heavily pre-treated patients who had undergone multiple previous lines of therapy, with a median of 5.5 prior treatments. Despite their challenging medical histories, the results were highly promising: 100% of the patients achieved a clinical response, with five out of eight (62.5%) achieving a stringent complete response, meaning no detectable traces of cancer cells post-treatment.

This is a remarkable achievement, as the stringent complete response rate is a key measure of the treatment’s efficacy. Not only did the patients respond to the therapy, but the trial also demonstrated a strong safety profile. One of the most common risks associated with CAR-T cell therapies is the onset of Cytokine Release Syndrome (CRS) or neurotoxicity, both of which can be severe and life-threatening. However, none of the patients in this trial experienced high-grade CRS or neurotoxicity, a significant marker of the therapy’s tolerability.

Following the success of Phase 1, the Drugs Controller General of India (DCGI) has granted approval for the trial to move into Phase 2. This will allow Aurigene to expand the trial and assess the therapy’s effectiveness on a larger patient population. The results of this early-stage study were presented at the 21st Annual Meeting of the International Myeloma Society in Rio de Janeiro, garnering international recognition for this pioneering treatment.

Strategic Importance for Dr. Reddy’s

This CAR-T cell therapy development marks a crucial moment in Dr. Reddy’s broader strategy to expand its footprint in oncology and advanced biologics. Traditionally known for its leadership in the generics market, Dr. Reddy’s has made significant strides in building its portfolio of innovative therapies, including biosimilars and now CAR-T cell treatments.

In its most recent financial results for Q1FY25, Dr. Reddy’s reported consolidated revenues of ₹7,673 crore (US$921 million), reflecting the company’s strong performance across key markets, including North America and India. The company’s ongoing efforts to diversify into high-value segments like oncology, biosimilars, and consumer healthcare are part of a long-term strategy to deliver sustainable growth and value to shareholders.

Advancing Cancer Treatment in India

Dr. Murali Ramachandra, CEO of Aurigene Oncology, expressed optimism about the results, noting that this breakthrough could be transformative for Indian patients who currently have limited access to cutting-edge cancer treatments. As India’s first autologous CAR-T therapy, Ribrecabtagene autoleucel represents a milestone in the country’s ability to develop and deliver advanced biotechnological solutions.

The company’s ability to conduct this trial in India is significant, as CAR-T therapies have historically been prohibitively expensive and largely available only in markets like the U.S. and Europe. By developing this therapy domestically, Dr. Reddy’s and Aurigene are setting the stage for broader access to life-saving cancer treatments within the Indian healthcare system.

Complementing Dr. Reddy’s Broader Strategic Moves

This breakthrough in CAR-T therapy complements Dr. Reddy’s broader initiatives across the healthcare sector. The company has been steadily expanding its biosimilars portfolio, with key partnerships like the one with Alvotech to commercialize biosimilar denosumab in the U.S. and Europe. Additionally, Dr. Reddy’s acquisition of the Nicotinell® brand and its joint venture with Nestlé India to bring nutraceutical products to market reflect the company’s growing presence in consumer healthcare and wellness.

Dr. Reddy’s is also leveraging its strong financial position—highlighted by a cash surplus of ₹6,731 crore (US$808 million)—to invest in future growth areas. The company’s focus on high-growth therapeutic areas like biosimilars and oncology, alongside its established generics business, positions it well for long-term value creation.

Looking Ahead

With the approval to move to Phase 2, Aurigene’s Ribrecabtagene autoleucel is on track to potentially become a groundbreaking treatment for multiple myeloma patients in India and potentially other markets. This achievement underscores Dr. Reddy’s ability to innovate in advanced therapies and aligns with its strategy to develop high-impact, cutting-edge treatments.

As Aurigene progresses through the next stages of clinical trials, investors and healthcare professionals alike will be closely watching for further data. If subsequent trials continue to show the same level of efficacy and safety, Ribrecabtagene autoleucel could become a pivotal treatment in the oncology space, not only transforming cancer care in India but also elevating Dr. Reddy’s standing as a global leader in innovative pharmaceutical solutions.

This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. The Author, Global Markets News Network, is a commercially operated digital brand compensated to provide coverage of news and developments innovative companies including the one aforementioned as detailed in the full documentation and it is thus subject to conflicts of interest. This article may include forward looking statements which cannot be guaranteed as discussed in the documentation. [ https://justpaste.it/fabrg/pdf ]

Media Contact
Company Name: Global Markets News Network
Contact Person: Editorial Desk
Email: Send Email
Country: India
Website: https://www.futuremarketsresearch.com/global-markets-news